Coherus Biosciences announces divestiture of YUSIMRY in $40M transaction

Coherus BioSciences agreed to divest YUSIMRY to Hong Kong King-Friend Industrial for up-front all-cash consideration of $40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the U.S. Coherus’ oncology assets include LOQTORZI, an FDA-approved, next-generation PD-1 inhibitor, the UDENYCA franchise, with three FDA-approved presentations; and an innovative clinical-stage, immuno-oncology portfolio focused on the tumor microenvironment.